retatrutide for diabetes type 2 More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Phase 2 Trial of Retatrutide

Liraglutide has been reported to lower the BMI by approximately 5% (55) and semaglutide with an average of 15% compared to a placebo (56)

It is a hormone that your body naturally produces in the gut

Central administration of human opiorphin alleviates dextran sodium sulfate-induced colitis in mice through activation of the endogenous opioid system

Our priority at Family Health Care is to provide personalized care and education for every member of your family

Determinants of hyperhomocysteinemia in healthy and hypertensive subjects: A population-based study and systematic review

Effect of a-lipoic acid on vitamin C and vitamin E deficiencies